CIK 0001119774 · Accelerated filer
COMPUGEN LTD
Sign in to watch- Ticker
- CGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- other
- Phone
- 011-972-3-765-8585
- Business address
- 26 HAROKMIM STREET, BUILDING D, HOLON, Israel, 5885849
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-10 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −2,000 | 56,000 | ||
| 2026-04-10 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +1,125 | $0.83 | $933 | 30,500 |
| 2026-04-10 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +2,000 | $1.15 | $2K | 32,500 |
| 2026-04-10 | Levine Zurit SVP, Business Development | Sale 10b5-1 | −3,125 | $2.56 | $8K | 29,375 |
| 2026-04-10 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −1,125 | 5,625 | ||
| 2026-04-10 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −2,000 | 56,000 | ||
| 2026-04-08 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +4,375 | $0.83 | $4K | 33,750 |
| 2026-04-08 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +1,000 | $1.15 | $1K | 34,750 |
| 2026-04-08 | Levine Zurit SVP, Business Development | Sale 10b5-1 | −5,375 | $2.42 | $13K | 29,375 |
| 2026-04-08 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −4,375 | 6,750 | ||
| 2026-04-08 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −1,000 | 58,000 | ||
| 2026-04-07 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +2,500 | $0.83 | $2K | 31,875 |
| 2026-04-07 | Levine Zurit SVP, Business Development | Sale 10b5-1 | −2,500 | $2.30 | $6K | 29,375 |
| 2026-04-07 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −2,500 | 11,125 | ||
| 2026-04-01 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +2,500 | $0.83 | $2K | 31,875 |
| 2026-04-01 | Levine Zurit SVP, Business Development | Option exercise 10b5-1 | +1,000 | $1.15 | $1K | 32,875 |
| 2026-04-01 | Levine Zurit SVP, Business Development | Sale 10b5-1 | −3,500 | $2.20 | $8K | 29,375 |
| 2026-04-01 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −2,500 | 13,625 | ||
| 2026-04-01 | Levine Zurit SVP, Business Development | Option exercise · Share Option (right to buy) 10b5-1 | −1,000 | 59,000 | ||
| 2026-04-01 | Ophir Eran President and CEO | Option exercise 10b5-1 | +5,625 | $0.83 | $5K | 17,000 |
Page 3 of 4 · 65 trades